Cargando…

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting

Evolocumab has been shown to consistently reduce low-density lipoprotein cholesterol (LDL-C) across populations. The phase 3 studies included administration in the home-use and in-clinic settings but did not specifically evaluate the feasibility of home-use administration. Two clinical studies enrol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dent, Ricardo, Joshi, Raju, Stephen Djedjos, C., Legg, Jason, Elliott, Mary, Geller, Michelle, Meyer, Dawn, Somaratne, Ransi, Recknor, Chris, Weiss, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783317/ https://www.ncbi.nlm.nih.gov/pubmed/27066336 http://dx.doi.org/10.1186/s40064-016-1892-3

Ejemplares similares

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
por: Kuchimanchi, Mita, et al.
Publicado: (2018)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
por: Rosenson, Robert S., et al.
Publicado: (2019)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
por: Nelson, Adam J., et al.
Publicado: (2020)

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
por: Koren, Michael J., et al.
Publicado: (2020)

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
por: Gibbs, John P., et al.
Publicado: (2016)

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
por: Hang, Shyann, et al.
Publicado: (2021)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
por: Wan, Yuansheng, et al.
Publicado: (2023)

Functional risk for fracture by safe functional motion testing: a short version of the safe functional motion test
por: Recknor, Christopher P., et al.
Publicado: (2019)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Is propofol safe when administered to cirrhotic patients during sedative endoscopy?
por: Suh, Sang Jun, et al.
Publicado: (2014)

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes
por: Blom, Dirk J., et al.
Publicado: (2020)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
por: McCormack, Terry, et al.
Publicado: (2016)

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies
por: Stroes, Erik, et al.
Publicado: (2018)

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study
por: Blaha, V, et al.
Publicado: (2023)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients
por: Ou, Ziwei, et al.
Publicado: (2022)

Hospitalization in High Fracture Risk Older Adults with Osteoporosis Using the Safe Functional Motion Test: A Longitudinal Analysis
por: Van Dussen, Daniel J., et al.
Publicado: (2021)

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
por: Abdelmaseih, Ramy, et al.
Publicado: (2021)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
por: Li, Zhenxian, et al.
Publicado: (2023)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
por: Toth, Peter P., et al.
Publicado: (2017)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
por: Inoue, Ikuo, et al.
Publicado: (2020)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

EVOLOCUMAB TREATMENT FAILURE FOLLOWING COVID-19 MRNA VACCINATION
por: Park, Byung Joon, et al.
Publicado: (2022)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Evidence-based goals in LDL-C reduction
por: Soran, Handrean, et al.
Publicado: (2017)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rqjj4sh9modm2vvd6k7r8m9rl4